OLD National Bancorp IN Reduces Stock Position in Sanofi (NASDAQ:SNY)

OLD National Bancorp IN decreased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 27.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,651 shares of the company's stock after selling 6,722 shares during the quarter. OLD National Bancorp IN's holdings in Sanofi were worth $979,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SNY. McClarren Financial Advisors Inc. increased its stake in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi in the 4th quarter valued at about $31,000. Bessemer Group Inc. lifted its position in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after buying an additional 242 shares during the last quarter. Sierra Ocean LLC acquired a new position in Sanofi in the fourth quarter valued at approximately $44,000. Finally, UMB Bank n.a. boosted its position in Sanofi by 30.7% during the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after purchasing an additional 264 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Trading Up 2.6%

Shares of Sanofi stock traded up $1.27 during trading hours on Thursday, hitting $50.97. The company's stock had a trading volume of 1,140,752 shares, compared to its average volume of 2,382,524. The stock has a 50 day moving average of $51.49 and a 200 day moving average of $51.98. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a market capitalization of $125.00 billion, a PE ratio of 20.47, a price-to-earnings-growth ratio of 1.01 and a beta of 0.50.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the business earned $1.78 earnings per share. The company's revenue was down 11.0% on a year-over-year basis. Analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a $2.0369 dividend. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is currently 57.14%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SNY shares. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Finally, The Goldman Sachs Group started coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.